CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Vitamin D3drug
Likely dose
Vitamin D3 50,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02464059
NCT02464059Phase 2Completed
CompareCT.gov

Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD

University of North Carolina, Chapel Hill·interventional·Posted Jun 8, 2015·Updated Jul 24, 2020

In Brief

A Phase 2 clinical trial evaluating Vitamin D3 for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 23 participants across 2 sites.

Detailed Summary

This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this application would also provide the justification to study vitamin D as a therapy to improve lung health.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
CollaboratorsJohns Hopkins University

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 8, 2015
Enrollment StartNov 10, 2015
Primary CompletionApr 15, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.1 years ago

Interventions

Vitamin D3drug

Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.